| Autor: |
Larsson P; Transplantation Center, Sahlgrenska University Hospital, University of Gothenburg, 41345 Gothenburg, Sweden.; Department of Pathology, Sahlgrenska University Hospital, 41345 Gothenburg, Sweden., Englund B; Department of Nephrology, Danderyd Hospital, Karolinska Institute, 18288 Stockholm, Sweden., Ekberg J; Transplantation Center, Sahlgrenska University Hospital, University of Gothenburg, 41345 Gothenburg, Sweden., Felldin M; Transplantation Center, Sahlgrenska University Hospital, University of Gothenburg, 41345 Gothenburg, Sweden., Broecker V; Department of Pathology, Sahlgrenska University Hospital, 41345 Gothenburg, Sweden., Mjörnstedt L; Transplantation Center, Sahlgrenska University Hospital, University of Gothenburg, 41345 Gothenburg, Sweden., Baid-Agrawal S; Transplantation Center, Sahlgrenska University Hospital, University of Gothenburg, 41345 Gothenburg, Sweden. |
| Abstrakt: |
All chronic and treatment-resistant acute rejections are "difficult-to-treat" and lead to progressive loss of graft function in kidney transplant recipients (KTR), as no effective treatment exists for such rejections to date. We review our experience with a novel strategy to treat such rejections by adding everolimus as a "rescue" to conventional triple maintenance therapy with prednisolone, mycophenolate mofetil and calcineurin inhibitor. We retrospectively analysed data in 28 KTR who received everolimus-based quadruple therapy at our institution for biopsy-proven chronic active T cell-mediated or antibody-mediated rejection (n = 19) or treatment-resistant acute rejections (n = 9) between 2011-2017. The primary outcome was 5-year death-censored graft survival. Main secondary outcomes were response to treatment defined by stable or improved graft function, 5-year patient survival and discontinuation rate of treatment. The Kaplan-Meier estimate for 5-year death-censored graft survival was 79% in all patients, 90% for patients with chronic active T cell-mediated rejections, 78% for chronic active antibody-mediated rejection and 67% for acute rejections. Response to treatment was achieved in 43% and 5-year patient survival was 94%. Treatment was stopped in 12 (43%) patients due to adverse events. Everolimus-based maintenance quadruple therapy, despite high rate of everolimus discontinuation due to adverse events, may be a valid approach in a subset of kidney transplant recipients with such difficult-to-treat rejections, which otherwise would lead to a high rate of graft loss. |
